Developing Innovative
Best-in-Class Vaccines

Computationally Designed VLP Vaccines

By utilizing computationally designed proteins that self-assemble into virus-like particles (VLPs), we are able to readily manufacture VLPs displaying complex antigens to target significant unmet medical needs.

RSV and Covid-19 Vaccines

Our vaccine candidates for respiratory syncytial virus (RSV) and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes COVID-19, have the potential to induce high neutralizing antibody titers for more effective protection.

Icosavax is dedicated to advancing vaccines against severe life-threatening respiratory diseases to protect our most at-risk populations.


In the News

BioSpace: Icosavax Turns VLP Tech to COVID-19 Vaccine, with $16.5 Million in New Financing

Icosovax is turning its virus-like particle (VLP) technology to fight COVID-19. The news accompanies $16.5 million in new funding from the Bill and Melinda Gates Foundation and Open Philanthropy, and the publication of preclinical data in Cell.

Icosavax Launches COVID-19 Vaccine Program with Preclinical Data and $16.5 Million in New Funding

Preclinical data published in Cell show the company’s COVID-19 vaccine candidate induces high neutralizing antibody titers after a single administration

BioSpace: Icosavax’s Nanoparticle VLP-based Vaccine Offers First-in-Class Solution for RSV

BioSpace reporter Gail Dutton reports on Icosavax's computationally designed virus-like particle (VLP)